Investigational drug · Phase 2
HX009
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Biliary Tract Cancer, Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "HX009"
First trial start
2025
Jan 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HX009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Melanoma
Approved drugs for the same conditions: Melanoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HX009" as an intervention, largest first.
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT06708663 · 124 participants (planned) · Start Jan 17, 2025 · Primary completion Dec 31, 2027
Drug: HX009+IN10018 · For: Biliary Tract Cancer; Melanoma
Sites: Beijing, China
- Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid TumorsStatus unknown
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT05731752 · 80 participants (planned) · Start May 28, 2020 · Primary completion Dec 30, 2024
Drug: HX009 · For: Advanced Solid Tumors
Sites: Beijing, China
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT05189093 · 48 participants · Start Dec 31, 2021 · Primary completion Jun 25, 2025
Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection · For: Relapsed/Refractory Lymphoma
Sites: Beijing, China
- The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced MalignanciesCompleted
Waterstone Hanxbio Pty LtdIndustry
NCT04097769 · 21 participants · Start Jun 12, 2019 · Primary completion Mar 18, 2021
Drug: HX009 · For: Advanced Solid Tumor
Sites: Kogarah, Australia
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT04886271 · 20 participants · Start May 12, 2021 · Primary completion Jan 12, 2024
Drug: HX009 · For: Advanced Solid Tumor
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody.
Ke H, Yang T, Zhang F, et al. · Sci Rep 2024
- HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.
Ke H, Zhang F, Wang J, et al. · Sci Rep 2023
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.